Publication at First Faculty of Medicine |
2004
Abstract
In the recent years myocardial damage biomarkers have been the most rapidly developing part of clinical biochemistry. Implementation of new myocardial markers has been very fast, mostly without profound clinical and analytical experience.
Our report presents recommendations of medical societies which have been published since 1999. We give detailed information on suggested guidelines, issued by the US National Academy of Clinical Biochemistry in 2004, and also on determination and clinical application of acute coronary syndrome and heart failure biomarkers.